Federated Hermes, Inc. Reata Pharmaceuticals Inc Transaction History

Federated Hermes, Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$79.22 - $105.37 $74,546 - $99,153	-941 Reduced 5.64%	15,756 $1.61 Million
Q1 2023 May 08, 2023	BUY	$30.85 - $93.17 $515,102 - $1.56 Million	16,697 New	16,697 $1.52 Million
Q2 2020 Aug 13, 2020	SELL	$126.3 - $176.56 $381,804 - $533,740	-3,023 Closed	0 $0
Q1 2020 May 13, 2020	SELL	$124.16 - $247.74 $6.03 Million - $12 Million	-48,588 Reduced 94.14%	3,023 $436,000
Q4 2019 Feb 14, 2020	BUY	$74.57 - $217.92 $639,512 - $1.87 Million	8,576 Added 19.93%	51,611 $10.6 Million
Q3 2019 Nov 14, 2019	SELL	$71.26 - $95.75 $314,897 - $423,119	-4,419 Reduced 9.31%	43,035 $3.46 Million
Q2 2019 Aug 14, 2019	SELL	$77.72 - $94.35 $4.3 Million - $5.22 Million	-55,362 Reduced 53.85%	47,454 $4.48 Million
Q1 2019 May 10, 2019	BUY	$51.9 - $101.79 $2.25 Million - $4.41 Million	43,315 Added 72.8%	102,816 $8.79 Million
Q3 2018 Nov 13, 2018	BUY	$35.64 - $92.06 $2.12 Million - $5.48 Million	59,501 New	59,501 $4.87 Million

62.7K

Ticker RETA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,583,200
Description
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney diseas...

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

Stay updated on Federated Hermes, Inc. with notifications on news.